Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer
Three cycles of neoadjuvant nivolumab plus chemotherapy significantly improved overall survival among patients with resectable NSCLC as compared with chemotherapy alone. (Funded by Bristol Myers Squibb; CheckMate 816 ClinicalTrials.gov number, NCT02998528.).
Authors
- S. Meadows–Shropshire
- Tudor–Eliade Ciuleanu (ORCID: https://orcid.org/0000-0003-0958-5597)
- Steven Swanson (ORCID: https://orcid.org/0000-0002-5896-1037)
- Simi Bhatia
- Gene B. Saylors
- Moïshe Liberman (ORCID: https://orcid.org/0000-0002-9964-1232)
- Julie R. Brahmer (ORCID: https://orcid.org/0000-0002-2443-8395)
- Joseph Fiore
- Stephen Broderick (ORCID: https://orcid.org/0000-0001-5905-4714)
- Fumihiro Tanaka
- Janis M. Taube (ORCID: https://orcid.org/0000-0002-8273-4395)
- Quyen Duong
- Hiroyuki Ito (ORCID: https://orcid.org/0000-0003-0983-6093)
- Lily Wang
- Claudio Martín (ORCID: https://orcid.org/0000-0003-4135-7332)
- Jonathan Spicer (ORCID: https://orcid.org/0000-0003-2708-1309)
- Patrick M. Forde (ORCID: https://orcid.org/0000-0001-6925-6344)
- Tetsuya Mitsudomi (ORCID: https://orcid.org/0000-0001-9860-8505)
- Mariano Provencio (ORCID: https://orcid.org/0000-0001-6315-7919)
- Mark M. Awad (ORCID: https://orcid.org/0000-0003-0928-5244)
- Enriqueta Felip (ORCID: https://orcid.org/0000-0002-7620-0098)
- Nicolas M Girard (ORCID: https://orcid.org/0000-0001-9909-2299)
- Changli Wang (ORCID: https://orcid.org/0000-0003-1075-5071)
- Junliang Cai
- Ke-Neng Chen
- Keith M. Kerr
- Shun Lu
Institutions
- Hebron University (PS)
- Brigham and Women's Hospital (US)
- Bloomberg (United States) (US)
- Memorial Sloan Kettering Cancer Center (US)
- Johns Hopkins University (US)
- Shanghai Jiao Tong University (CN)
- University of Occupational and Environmental Health Japan (JP)
- Peking University (CN)
- Trinity College Dublin (IE)
- Johns Hopkins Medicine (US)
- Aberdeen Royal Infirmary (GB)
- Cancer Institute (WIA) (IN)
- McGill University Health Centre (CA)
- Tianjin Medical University Cancer Institute and Hospital (CN)
- Shanghai Chest Hospital (CN)
- Kanagawa Prefectural Hospital Organization (JP)
- Bristol-Myers Squibb (United States) (US)
- Peking University Cancer Hospital (CN)
- Institute of Oncology Prof. Dr. Ion Chiricuta (RO)
- Hospital Universitario Puerta de Hierro Majadahonda (ES)
- Instituto Alexander Fleming (AR)
- Centre Hospitalier de l’Université de Montréal (CA)
- Institut du Thorax (FR)
- Molecular Oncology (United States) (US)
- Sidney Kimmel Comprehensive Cancer Center (US)
- Kanagawa Cancer Center
- Vall d'Hebron Institute of Oncology (ES)
- Institut Curie (FR)
- Kindai University (JP)
Publication Details
- Journal
- New England Journal of Medicine
- Published
- 2025-06-02
- DOI
- https://doi.org/10.1056/nejmoa2502931
- Citations
- 94
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 98.27
Funders
- Bristol-Myers Squibb